Translate Bio, which is developing mRNA therapeutic treatments for cystic fibrosis, announced terms for its IPO on Monday.
The Lexington, MA-based company plans to raise $100 million by offering 7.7 million shares at a price range of $12 to $14. Insiders intend to purchase $50 million worth of shares in the offering. At the midpoint of the proposed range, Translate Bio would command a market value of $561 million.
Translate Bio was founded in 2011 and plans to list on the Nasdaq under the symbol TBIO. Citi, Leerink Partners and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of June 25, 2018.
